maritide obesity drug news - Search News

What's Next for Amgen Obesity Drug

Newsweek on MSN · 2h

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

BioPharma Dive · 9h

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

CNBC on MSN · 14h

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

7hon MSN

Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

FierceBiotech12h

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Benzinga.com17h

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results